CL2019002601A1 - Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. - Google Patents

Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.

Info

Publication number
CL2019002601A1
CL2019002601A1 CL2019002601A CL2019002601A CL2019002601A1 CL 2019002601 A1 CL2019002601 A1 CL 2019002601A1 CL 2019002601 A CL2019002601 A CL 2019002601A CL 2019002601 A CL2019002601 A CL 2019002601A CL 2019002601 A1 CL2019002601 A1 CL 2019002601A1
Authority
CL
Chile
Prior art keywords
conditions
post
medical
treatment methods
alicyclics
Prior art date
Application number
CL2019002601A
Other languages
English (en)
Inventor
János Éles
István Borza
Viktor Román
Zsuzsa Hadady
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CL2019002601A1 publication Critical patent/CL2019002601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Abstract

NUEVOS DERIVADOS DE PIRAZOL[1,5-A]PIRIMIDINA DE LA FÓRMULA (I) O SALES FARMACÉUTICAMENTE ACEPTABLES, METABOLITOS BIOLÓGICAMENTE ACTIVOS, PROFÁRMACOS, RACEMATOS, ENANTIÓMEROS, DIASTEREÓMEROS, SOLVATOS E HIDRATOS DE LOS MISMOS QUE SIRVEN COMO MODULADORES ALOSTÉRICOS POSITIVOS DEL RECEPTOR DEL GABAB. LA INVENCIÓN TAMBIÉN SE RELACIONA CON EL PROCESO PARA PRODUCIR DICHOS COMPUESTOS. LA INVENCIÓN SE RELACIONA ADEMÁS CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, OPCIONALMENTE EN COMBINACIÓN CON DOS O MÁS AGENTES TERAPÉUTICOS DIFERENTES, Y CON EL USO DE DICHOS COMPUESTOS EN MÉTODOS DE TRATAMIENTO DE ENFERMEDADES Y CONDICIONES MEDIADAS Y MODULADAS POR EL MECANISMO ALOSTÉRICO POSITIVO DEL RECEPTOR DEL GABAB. LA INVENCIÓN TAMBIÉN PROVEE UN MÉTODO PARA ELABORAR MEDICAMENTOS QUE SON DE UTILIDAD EN EL TRATAMIENTO DE DICHOS TRASTORNOS.
CL2019002601A 2017-03-13 2019-09-12 Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. CL2019002601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok

Publications (1)

Publication Number Publication Date
CL2019002601A1 true CL2019002601A1 (es) 2020-01-24

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002601A CL2019002601A1 (es) 2017-03-13 2019-09-12 Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.

Country Status (32)

Country Link
US (1) US11026946B2 (es)
EP (1) EP3596080B1 (es)
JP (1) JP7153662B2 (es)
KR (1) KR20190127779A (es)
CN (1) CN110431142A (es)
AR (1) AR111176A1 (es)
AU (1) AU2018235266B2 (es)
BR (1) BR112019018843A2 (es)
CA (1) CA3056185A1 (es)
CL (1) CL2019002601A1 (es)
CO (1) CO2019010120A2 (es)
CY (1) CY1124708T1 (es)
DK (1) DK3596080T3 (es)
EA (1) EA038756B1 (es)
EC (1) ECSP19072975A (es)
ES (1) ES2893824T3 (es)
GE (1) GEP20217256B (es)
HR (1) HRP20211850T1 (es)
HU (2) HU231058B1 (es)
IL (1) IL268923A (es)
LT (1) LT3596080T (es)
MX (1) MX2019011000A (es)
MY (1) MY195262A (es)
PE (1) PE20191646A1 (es)
PH (1) PH12019501968A1 (es)
PL (1) PL3596080T3 (es)
PT (1) PT3596080T (es)
RS (1) RS62533B1 (es)
SG (1) SG11201907864YA (es)
SI (1) SI3596080T1 (es)
UA (1) UA124783C2 (es)
WO (1) WO2018167630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094828A1 (en) 2004-03-02 2005-10-13 F. Hoffmann-La Roche Ag 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR100753017B1 (ko) * 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-a]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
JP5432982B2 (ja) * 2008-03-31 2014-03-05 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ1阻害剤
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
EP3286192A1 (en) 2015-04-20 2018-02-28 AbbVie Deutschland GmbH & Co KG Substituted pyrazolopyrimidines and method of use
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Also Published As

Publication number Publication date
HUP1700108A2 (en) 2018-09-28
SG11201907864YA (en) 2019-09-27
EA038756B1 (ru) 2021-10-14
CY1124708T1 (el) 2022-07-22
WO2018167630A1 (en) 2018-09-20
BR112019018843A2 (pt) 2020-04-14
AU2018235266A1 (en) 2019-10-17
HRP20211850T1 (hr) 2022-03-04
EP3596080B1 (en) 2021-09-01
ES2893824T3 (es) 2022-02-10
AU2018235266B2 (en) 2021-09-30
JP7153662B2 (ja) 2022-10-14
HU231058B1 (hu) 2020-04-28
PE20191646A1 (es) 2019-11-07
UA124783C2 (uk) 2021-11-17
PL3596080T3 (pl) 2022-01-31
CA3056185A1 (en) 2018-09-20
US11026946B2 (en) 2021-06-08
MX2019011000A (es) 2019-10-17
PT3596080T (pt) 2021-10-22
PH12019501968A1 (en) 2020-06-29
HUE056562T2 (hu) 2022-02-28
JP2020510041A (ja) 2020-04-02
SI3596080T1 (sl) 2022-01-31
MY195262A (en) 2023-01-11
GEP20217256B (en) 2021-05-25
EP3596080A1 (en) 2020-01-22
CO2019010120A2 (es) 2019-10-09
EA201992127A1 (ru) 2020-02-06
KR20190127779A (ko) 2019-11-13
CN110431142A (zh) 2019-11-08
AR111176A1 (es) 2019-06-12
LT3596080T (lt) 2021-11-25
ECSP19072975A (es) 2019-11-30
DK3596080T3 (da) 2021-11-15
IL268923A (en) 2019-10-31
RS62533B1 (sr) 2021-11-30
US20200129515A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
CO2017000912A2 (es) Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MX2020000268A (es) Agonista de fxr.
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
ECSP21037191A (es) Pirazoles como moduladores de la hemoglobina
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2018002574A (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CL2008001112A1 (es) Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
CL2023000352A1 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
WO2020106454A3 (en) Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction